Results 71 to 80 of about 4,918,610 (234)

Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor–related intracranial hemorrhage in the US

open access: yes, 2022
To conduct a cost-effectiveness analysis (CEA) on the use of andexanet alfa for the treatment of factor Xa inhibitor-related intracranial hemorrhage (ICH) from the United States (US) third-party payer and societal perspectives.
Filipa Aragão (307309)   +5 more
core   +1 more source

Diagnostic value of plasma TFF3‐centered combined biomarker panel in early gastrointestinal cancer

open access: yesVIEW, EarlyView.
In this study, a retrospective cohort was established, including gastrointestinal cancer, non‐GI cancer, and healthy controls. TFF3, CEA, and gastric function indicators were detected. TFF3 showed significantly better diagnostic performance compared with conventional gastrointestinal indicators in gastric cancer, and compared with CEA in ...
Yizhou Huang   +7 more
wiley   +1 more source

Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays

open access: yes, 2018
Edoxaban is an oral direct factor Xa inhibitor for prophylaxis and treatment of thromboembolic disorders. The effects on common coagulation assays are clinically valuable information and in certain clinical situations a quick assessment of the ...
Lindahl, T. L.   +25 more
core   +1 more source

Evolutionary Mechanisms of Coagulation Factors in Cetaceans During Aquatic Adaptation

open access: yesIntegrative Zoology, EarlyView.
Compared with Bos taurus, T. truncatus showed shorter prothrombin time and thrombin time but prolonged activated partial thromboplastin time, indicating pathway‐specific remodeling of coagulation. Evolutionary analyses identified 18 positively selected genes and accelerated F11 evolution, while functional assays revealed increased coagulation factor ...
Wenjun Lv   +4 more
wiley   +1 more source

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

open access: yesStroke: Vascular and Interventional Neurology
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa ...
Mauricio Concha   +10 more
doaj   +1 more source

Factor Xa Acts as a PDGF-Independent Mitogen in Human Vascular Smooth Muscle Cells

open access: yes, 2000
SummaryThis study investigates the mitogenic effect of the coagulation factor Xa in smooth muscle cells (SMC) from human saphenous vein and the procoagulant activity of these cells.
Michael Wittpoth   +5 more
core   +1 more source

Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells [PDF]

open access: yes, 1998
Proinflammatory effects induced by the serine protease factor Xa were investigated in HUVEC. Exposure of cells to factor Xa (5-80 nM) concentration dependently stimulated the production of IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) and the ...
Buurman, W.A.   +13 more
core   +1 more source

Microbiome Dynamics During Translocation of the Critically Endangered Frog Craugastor ranoides

open access: yesAnimal Conservation, EarlyView.
A female Craugastor ranoides fitted with an LB‐2X radio transmitter using a silicone waist‐belt harness for post‐translocation monitoring. ABSTRACT Amphibian populations are declining, and species are going extinct due to habitat loss, climate change, and emerging infectious disease, prompting the increasing use of translocations as a conservation tool.
Xavier A. Harrison   +11 more
wiley   +1 more source

Factor Xa Inhibitors [PDF]

open access: yes, 2016
Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Eduard Shantsila, Gregory YH Lip
openaire   +1 more source

Studies of factor Xa/phospholipid-induced intravascular coagulation in rabbits. Effects of immunodepletion of tissue factor pathway inhibitor.

open access: yes, 1993
In earlier studies from this laboratory evidence was obtained for a physiological function of tissue factor pathway inhibitor (TFPI) as a regulator of hemostasis capable of preventing thrombotic complications that might otherwise result from exposure of ...
S I Rapaport, B J Warn-Cramer
core   +1 more source

Home - About - Disclaimer - Privacy